Through pan-cancer transcriptomic analysis, ORMDL2 was shown to be overexpressed in brain tumor tissues relative to normal brain tissues, with its expression correlating significantly with clinical features such as IDH mutation status, MGMT promoter methylation, and World Health Organization (WHO) grade. Here, ORMDL2 is linked to brain neoplasm.